Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie 
Welcome,         Profile    Billing    Logout  
 19 Diseases   1 Trial   1 Trial   3388 News 


«12...2223242526272829303132...4849»
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Journal:  Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants. (Pubmed Central) -  Mar 23, 2022   
    By analyzing two CZA-resistant KPC-3 clinical variants, KPC-41 and KPC-50, we showed that KPC-41, and to a lesser extent KPC-50, may also have an impact on susceptibility to FDC leading to a cross-resistance. This feature highlights that a susceptibility testing to FDC is mandatory prior any clinical use of FDC for treating infections due to KPC producers.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    CEFTAZIDIME-AVIBACTAM ACTIVITY AGAINST GRAM-NEGATIVE BACTERIA FROM BLOODSTREAM INFECTIONS ([VIRTUAL]) -  Mar 23, 2022 - Abstract #SCCM2022SCCM_1694;    
    Ceftolozane-tazobactam (C-T) was active against 95.5% of ENT, but showed limited activity against ESBL producers (84.1%S), MDR ENT (68.9%S) and E. cloacae (n=318; 85.8%S)...PSA susceptibility to PIP-TAZ, MEM and cefepime was 85.0%, 86.4% and 88.9%, respectively... CAZ-AVI showed potent in vitro activity and broad spectrum against ENT (99.9%S) and PSA (96.4%) isolated from patients with BSI from US hospitals.
  • ||||||||||  Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    ANTIMICROBIAL SUSCEPTIBILITY OF PSEUDOMONAS AERUGINOSA AND KLEBSIELLA PNEUMONIAE CAUSING PNEUMONIA ([VIRTUAL]) -  Mar 23, 2022 - Abstract #SCCM2022SCCM_1621;    
    CAZ-AVI and MEM-VAB were the most active compounds against KPN (99.6-99.7%S). Recently approved beta-lactam inhibitor combinations markedly improved the armamentarium against MDR PSA and KPN causing pneumonia in US hospitals.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Journal:  Multidrug-resistant Klebsiella pneumoniae: mechanisms of resistance including updated data for novel β-lactam-β-lactamase inhibitor combinations. (Pubmed Central) -  Mar 17, 2022   
    Soon after the launch of Ceftazidime-Avibactam, one of the approved new β-lactam/β-lactamase inhibitor combinations, reports of ceftazidime-avibactam-resistant strains developing resistance during treatment were published...Following the development of drug resistance and understanding the mechanisms involved, we can improve the efficacy of current antimicrobials, by applying careful stewardship and rational use to preserve their potential utility. The knowledge on antibiotic resistance mechanisms should be used to inform the design of novel therapeutic agents that might not be subject to, or can circumvent, mechanisms of resistance.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Retrospective data, Journal:  Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa. (Pubmed Central) -  Mar 17, 2022   
    The knowledge on antibiotic resistance mechanisms should be used to inform the design of novel therapeutic agents that might not be subject to, or can circumvent, mechanisms of resistance. CAZ-AVI constitutes a valid alternative for the treatment of infections due to MDR/XDR P. aeruginosa.
  • ||||||||||  Review, Journal:  Carbapenemase-producing Enterobacterales infections: Recent advances in diagnosis and treatment. (Pubmed Central) -  Mar 17, 2022   
    Recently, several novel agents have been approved for clinical use, such as ceftazidime/avibactam, ceftolozane/tazobactam, cefiderocol, eravacycline, omadacycline, meropenem/vaborbactam, imipenem/cilastatin/relebactam and plazomicin...Here, recent advances in the methods for the identification of CPE have been reviewed, including phenotypic methods (carbapenemase inactivation methods), biochemical methods (Carbapenemase Nordmann-Poirel (Carba NP) test and modified Carba NP test), immunochromatographic methods, proteomic methods (matrix-assisted laser desorption/ionization time-of-flight mass spectrometry), and molecular-based methods (nucleic acid amplification technologies, hybridization techniques (microarray), and whole-genome sequencing). Both precise diagnosis and adequate treatment are important to combat the emerging CPE crisis.
  • ||||||||||  Zerbaxa (ceftolozane /tazobactam) / Merck (MSD)
    Clinical, Journal:  Modifiable Risk Factors for the Emergence of Ceftolozane-Tazobactam Resistance. (Pubmed Central) -  Mar 15, 2022   
    Due to our small sample size, our results remain exploratory but forewarn of the potential emergence of TOL-TAZ resistance during therapy and suggest extending TOL-TAZ infusions may be protective. Larger studies are needed to investigate this association.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Journal:  Comparison of Four Carbapenemase Detection Methods for bla Variants. (Pubmed Central) -  Mar 12, 2022   
    Recently, various bla variants resistant to ceftazidime-avibactam have begun to emerge in clinical settings, but it is unclear which testing method is most appropriate for detecting these variants...GeneXpert Carba-R could detect six bla variants carried by all 19 K. pneumoniae. This study may be valuable for clinical laboratories in their efforts to test for various bla variants.
  • ||||||||||  Vabomere (meropenem/vaborbactam) / Melinta Therap
    Journal:  Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing Klebsiella pneumoniae: a multicentre study. (Pubmed Central) -  Mar 11, 2022   
    The single adverse event observed consisted of severe leukopenia with thrombocytopenia. With the well-known limitations of real-life retrospective studies, our results support previous findings indicating that meropenem/vaborbactam therapy will be a safe, effective tool for managing serious KPC-Kp infections, including the increasing proportion displaying resistance to ceftazidime/avibactam.
  • ||||||||||  Xerava (eravacycline) / SOM Biotech, Ewha Womans University, La Jolla Pharma, PAION, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Clinical, Journal:  Ceftazidime/avibactam and eravacycline susceptibility of carbapenem-resistant Klebsiella pneumoniae in two Greek tertiary teaching hospitals. (Pubmed Central) -  Mar 8, 2022   
    The blaKPC gene was present in 30 strains (63.8%), the blaNDM in 11 (23.4%) and the blaVIM in 6 (12.8%). The blaOXA-48 gene was not detected.Well established antimicrobial agents such as colistin, gentamicin and tigecycline and novel antibiotics like ceftazidime/avibactam and eravacycline can be reliable options for the treatment of invasive infections caused by carbapenem-resistant K. pneumoniae.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Cost-Effectiveness of Ceftazidime/Avibactam Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections in China (Virtual) -  Mar 8, 2022 - Abstract #ISPOR2022ISPOR_1137;    
    The blaOXA-48 gene was not detected.Well established antimicrobial agents such as colistin, gentamicin and tigecycline and novel antibiotics like ceftazidime/avibactam and eravacycline can be reliable options for the treatment of invasive infections caused by carbapenem-resistant K. pneumoniae. Ceftazidime/avibactam versus meropenem is not economical in the treatment of cIAIs.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Journal:  Ceftazidime/Avibactam versus Polymyxin B in the Challenge of Carbapenem-Resistant Pseudomonas aeruginosa Infection. (Pubmed Central) -  Mar 5, 2022   
    The multivariate COX analysis showed that the age was identified as independent predictor of 30-day mortality while CAZ/AVI therapy and central venous catheterization emerged as independent predictors of 30-day survival. CAZ/AVI therapy was superior to polymyxin B therapy for patients with CRPA infection, and provided significant survival benefits, but further larger studies were needed to substantiate our findings.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Clinical, PK/PD data, Journal:  Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime-Avibactam in Pediatric Patients Aged 3 Months and Older. (Pubmed Central) -  Mar 1, 2022   
    P1, P2
    This paper describes the development of updated combined adult and pediatric population PK models and their application in characterizing the population PK of ceftazidime and avibactam in children, and in dose selection for further pediatric evaluation. The updated models supported the approval of ceftazidime-avibactam pediatric dosage regimens (all by 2-hour IV infusion) of 50-12.5 mg/kg (maximum 2000-500 mg) q8h for those ≥6 months to 18 years old, and 40-10 mg/kg q8h for those ≥3 to 6 months old with creatinine clearance >50 mL/min/1.73 m .
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Clinical, Journal:  Prevalence of O25b-ST131 Escherichia coli Clone: Fecal Carriage of Extended-Spectrum β-Lactamase and Carbapenemase-Producing Isolates in Healthy Adults in Tehran, Iran. (Pubmed Central) -  Mar 1, 2022   
    This study aimed at determining the prevalence rate and molecular epidemiology of extended-spectrum β-lactamase-producing E. coli (ESBL-Ec), carbapenemase-producing E. coli (CPEc), ceftazidime/avibactam (CAZ/AVI)-resistant E. coli, and ST131 isolates in healthy fecal carriers in Tehran, Iran...Our findings disclose that the presence of carbapenem-resistant ST131 isolates, which are also resistant to CAZ/AVI, contributes to the spread of resistant strains in the community. Therefore, screening and monitoring of such resistant clone in healthy people is necessary.
  • ||||||||||  Review, Journal:  Urinary tract infections in nephrology: antibiotic therapy in the era of antibiotic resistance (Pubmed Central) -  Mar 1, 2022   
    On the other hand, ceftolozane/tazobactam, ceftazidime/avibactam, cefiderocol, imipenem/cilastatin/relebactam and meropenem-vaborbactam are very promising new antibiotics. Ongoing clinical studies will be able to determine the place for these interesting molecules in the treatment of infections and in fighting AMR.
  • ||||||||||  aztreonam-avibactam (PF-06947387) / Pfizer, AbbVie, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Review, Journal:  Treatment of Severe Infections Due to Metallo-Betalactamases Enterobacterales in Critically Ill Patients. (Pubmed Central) -  Feb 26, 2022   
    Colistin, fosfomycin, tetracyclines and aminoglycosides are also frequently effective in vitro, but are associated with less bactericidal activity or more toxicity...To conclude, treatment of severe MBL infections in critically ill patients is difficult. It should be individualized with a close collaboration of intensivists with microbiologists, pharmacists and infection control practitioners.
  • ||||||||||  colistin sulphate / Generic mfg.
    Journal:  XDR-Pseudomonas aeruginosa Outside the ICU: Is There Still Place for Colistin? (Pubmed Central) -  Feb 26, 2022   
    In such a setting, ceftolozane/tazobactam and ceftazidime/avibactam should be administered with caution taking into account the microbiological susceptibility results. Colistin, even with its known safety and efficacy limits, could represent the only available therapeutic option due to its highly preserved susceptibility against XDR isolates of P. aeruginosa.
  • ||||||||||  colistin sulphate / Generic mfg.
    Review, Journal:  The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations. (Pubmed Central) -  Feb 26, 2022   
    Nevertheless, colistin may be needed for the treatment of CRAB infections and in the setting where the new BLBLIs are currently unavailable. In addition, with the advent of rapid diagnostic methods and novel antimicrobials, the application of personalized medicine has gained significant importance in the treatment of CRE infections.